Novel Therapeutics and Endothelial Dysfunction in T1DM Patients (ENDIS)
Endothelial Dysfunction, Diabetes Mellitus, Type 1, Biomarkers
About this trial
This is an interventional treatment trial for Endothelial Dysfunction
Eligibility Criteria
Inclusion Criteria: T1DM HbA1C<=9% prone to CGM system 20 - 70 years Exclusion Criteria: HbA1C >9%, BMI<22, pregnancy or lactation, known hypersensitivity to study drug, malignant disease ( excluded >5 years disease free, bazocellular or planocellular ca of skin), liver cirrhosis child C, eGFR<60 ml/min, chronic inflammatory disease, proliferative diabetic rethinopathy, MEN or medullary thyroid cancer in familly, concomitant drugs with influence on glycemia and antiinflammatory influence (corticosteroids, immunosupresive therapy), Major cardiovascular event last 2 months ( stroke, MI)
Sites / Locations
- General Hospital Celje
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Active Comparator
No Intervention
GLP 1 agonist
SGLT 2 inhibitor
comparator
semaglutide in titrating doses 0,25 to 1,0 mg - duration of treatment12 weeks adding to insulin sheme (MDI or CII)
empagliflozin 25 mg - duration of treatment 12 weeks adding to insulin sheme (MDI or CII or hybride system)
continuing treatment only with insulin sheme (MDI or CII or hybride system)